

FINAL EXAM  
 DECEMBER 2015

NATIONAL BOARD OF EXAMINATIONS

**NEPHROLOGY**
**PAPER – III**

NEPH/D/15/20/III

Time : 3 hours

Max. Marks : 100

**Important instructions:**

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

**Write short notes on:**

1.	Acquired renal cystic disease under the following heads: a) Diagnosis b) Prevalence c) Complications d) Management	2 2 3 3
2.	Registries (National and International) as research tool.	10
3.	a) Steroid avoidance in renal transplant - pros and cons. b) Clinical usage of mTOR inhibitors in renal transplant patients.	5 5
4.	Hemodialfiltration in maintenance dialysis patients under the following headings: a) Technical requirements. b) Global usage pattern. c) Clinical outcomes.	5 2 3
5.	ABO incompatible renal transplants under the following headings: a) Historical perspective. b) Current clinical protocols. c) Outcomes as compared to compatible renal transplantation.	2 6 2
6.	Vaccinations under the following headings: a) Chronic kidney disease – predialysis and dialysis patients. b) Vaccinations to be avoided in post renal transplant patients.	6 4
7.	a) Revised Chapel-Hill classification of vasculitis. b) Mention the important differences from the previous classification.	7 3
8.	a) Enumerate the markers of iron status in CKD with their normal values. b) Diagnosis and treatment of iron overload. c) Newer erythropoiesis stimulating agents.	3 (2+2) 3
		<b>P.T.O.</b>

FINAL EXAM  
 DECEMBER 2015

NATIONAL BOARD OF EXAMINATIONS

<b><u>NEPHROLOGY</u></b>	
<b>PAPER – III</b>	
9. a) Current classification of plasma cell dyscrasias. b) Diagnosis and treatment of myeloma kidney.	<b>5</b> <b>(2+3)</b>
10. The Transplantation of Human Organs and Tissues Act, 2011 under the following heads: a) Important differences from THOA, 1994 b) Salient requirements of a centre to be recognized for transplantation.	<b>5</b> <b>5</b>

\*\*\*\*\*

www.FirstRanker.com